Prestige Consumer Healthcare (NYSE:PBH) Upgraded at StockNews.com

Prestige Consumer Healthcare (NYSE:PBH) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Friday.

Several other research analysts also recently commented on the stock. DA Davidson reaffirmed a “buy” rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective on the stock. in a research report on Monday, December 9th. Finally, Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, Prestige Consumer Healthcare has a consensus rating of “Moderate Buy” and an average target price of $85.25.

Prestige Consumer Healthcare Trading Down 0.8 %

Shares of PBH opened at $76.79 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. Prestige Consumer Healthcare has a fifty-two week low of $60.00 and a fifty-two week high of $86.36. The firm has a 50 day moving average price of $80.31 and a 200-day moving average price of $74.76. The firm has a market cap of $3.79 billion, a price-to-earnings ratio of 18.68, a PEG ratio of 2.22 and a beta of 0.51.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. The company had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. Prestige Consumer Healthcare’s quarterly revenue was down .9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.07 EPS. As a group, equities research analysts forecast that Prestige Consumer Healthcare will post 4.46 earnings per share for the current year.

Insider Activity

In other news, CEO Ronald M. Lombardi sold 10,875 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the sale, the chief executive officer now owns 320,952 shares in the company, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider William P’pool sold 8,987 shares of the company’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total transaction of $735,585.95. Following the completion of the sale, the insider now directly owns 20,058 shares in the company, valued at $1,641,747.30. This represents a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 38,810 shares of company stock valued at $3,187,300. Corporate insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. boosted its position in shares of Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after purchasing an additional 433 shares in the last quarter. nVerses Capital LLC raised its stake in Prestige Consumer Healthcare by 200.0% during the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock valued at $43,000 after buying an additional 400 shares during the last quarter. Huntington National Bank boosted its holdings in Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after acquiring an additional 181 shares in the last quarter. International Assets Investment Management LLC grew its stake in shares of Prestige Consumer Healthcare by 7,112.5% in the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock worth $83,000 after acquiring an additional 1,138 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Prestige Consumer Healthcare by 49.9% during the third quarter. GAMMA Investing LLC now owns 1,163 shares of the company’s stock valued at $84,000 after acquiring an additional 387 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.